: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .
: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.
: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.
The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25
: £13.0 million (+52.9%), driven by AMR and EMEAI growth.
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :